Literature DB >> 707541

Early anthracycline cardiotoxicity.

M R Bristow, P D Thompson, R P Martin, J W Mason, M E Billingham, D C Harrison.   

Abstract

Eight patients in whom cardiac dysfunction developed within four weeks of receiving their first or second course of daunorubicin or doxorubicin are described. Four patients presented with pericarditis; three of these four had evidence of myocardial dysfunction. Histopathologic analysis of these patients was consistent with an acute myocyte damage and secondary inflammatory process. An additional group of four patients presented with symptoms and signs of heart failure. These patients were either elderly or had evidence of previous cardiac disease. One of these patients suffered a myocardial infarction 24 hours after receiving 60 mg/m2 of daunorubicin; earlier doses in the same course had been associated with evidence of myocardial ischemia. We conclude that anthracycline antibiotics may manifest clinically significant cardiotoxicity at total cumulative doses much less than have been associated with chronic cardiomyopathy.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 707541     DOI: 10.1016/0002-9343(78)90802-1

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  75 in total

1.  The development of congestive heart failure and ventricular tachycardia after first exposure to idarubicin in a patient with acute myeloid leukaemia.

Authors:  Szu-Cheng Yang; Mei-Hua Chuang; Dian-Kun Li
Journal:  Br J Clin Pharmacol       Date:  2010-02       Impact factor: 4.335

2.  Androgen receptor counteracts Doxorubicin-induced cardiotoxicity in male mice.

Authors:  Yasumasa Ikeda; Ken-ichi Aihara; Masashi Akaike; Takashi Sato; Kazue Ishikawa; Takayuki Ise; Shusuke Yagi; Takashi Iwase; Yuka Ueda; Sumiko Yoshida; Hiroyuki Azuma; Kenneth Walsh; Toshiaki Tamaki; Shigeaki Kato; Toshio Matsumoto
Journal:  Mol Endocrinol       Date:  2010-05-25

Review 3.  Nano-enabled delivery of diverse payloads across complex biological barriers.

Authors:  Kathleen A Ross; Timothy M Brenza; Andrea M Binnebose; Yashdeep Phanse; Anumantha G Kanthasamy; Howard E Gendelman; Aliasger K Salem; Lyric C Bartholomay; Bryan H Bellaire; Balaji Narasimhan
Journal:  J Control Release       Date:  2015-08-24       Impact factor: 9.776

4.  Myopericarditis in a pregnant woman with acute promyelocytic leukemia.

Authors:  Andrew Oehler; Shimoli Shah
Journal:  J Cardiol Cases       Date:  2014-08-19

Review 5.  Drug effects on the electrocardiogram. A review of their clinical importance.

Authors:  J D Symanski; L S Gettes
Journal:  Drugs       Date:  1993-08       Impact factor: 9.546

6.  Lipid lowering: an important factor in preventing adriamycin-induced heart failure.

Authors:  N Iliskovic; P K Singal
Journal:  Am J Pathol       Date:  1997-02       Impact factor: 4.307

Review 7.  A risk-benefit assessment of anthracycline antibiotics in antineoplastic therapy.

Authors:  R Abraham; R L Basser; M D Green
Journal:  Drug Saf       Date:  1996-12       Impact factor: 5.606

Review 8.  Rodent models of heart failure: an updated review.

Authors:  A C Gomes; I Falcão-Pires; A L Pires; C Brás-Silva; A F Leite-Moreira
Journal:  Heart Fail Rev       Date:  2013-03       Impact factor: 4.214

9.  Mitoxantrone: an overview of safety and toxicity.

Authors:  L E Posner; G Dukart; J Goldberg; T Bernstein; K Cartwright
Journal:  Invest New Drugs       Date:  1985       Impact factor: 3.850

Review 10.  Anthracycline Use for Early Stage Breast Cancer in the Modern Era: a Review.

Authors:  Sakshi Jasra; Jesus Anampa
Journal:  Curr Treat Options Oncol       Date:  2018-05-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.